Brief: Spectral Medical And Vantive Announce Topline 12 Month Follow-Up Results From Spectral’S Tigris Trial
04/06/2026 12:09
BRIEF-Spectral Medical And Vantive Announce Topline 12 Month Follow-Up Results From Spectral’S Tigris Trial June 4 (Reuters) - Spectral Medical Inc EDT.TO:
SPECTRAL MEDICAL AND VANTIVE ANNOUNCE TOPLINE 12 MONTH FOLLOW-UP RESULTS FROM SPECTRAL’S TIGRIS TRIAL
SPECTRAL MEDICAL - 100% FOLLOW-UP ACHIEVED FOR ALL 157 TIGRIS TRIAL PATIENTS
SPECTRAL MEDICAL - 12-MONTH MORTALITY 52.8% WITH PMX VERSUS 66.7% WITH STANDARD OF CARE IN TIGRIS TRIAL
SPECTRAL MEDICAL - ABSOLUTE RISK REDUCTION AT 12 MONTHS 13.9%, NUMBER NEEDED TO TREAT 7.2
SPECTRAL MEDICAL - 95.9% PROBABILITY OF BENEFIT FOR PMX AT 12 MONTHS BASED ON TIGRIS DATA
Source text: ID:nGNX23Gq0Y
Further company coverage: EDT.TO
((((Reuters.Briefs@thomsonreuters.com;));))
Recent news on Spectral Medical
See all newsBrief: Spectral Medical Provides Update Following In-Person FDA 100-Day Meeting For PMX PMA
Canada's Spectral Medical Q2 revenue falls on lower reagent sales
Brief: Spectral Medical And Vantive Announce Topline 12 Month Follow-Up Results From Spectral’S Tigris Trial
Canada's Spectral Medical Q1 revenue rises 56%, net loss narrows
Spectral Medical Q3 revenue up 34%